-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
May 2021
-
The 50-year Journey to Optimize Lung Cancer Screening Programs
The first forays into lung cancer screening began in the 1970s, with two trials evaluating the use of chest x-ray and sputum cytology to detect disease. Those trials showed no reductions in mortality, advocating against the practice of lung cancer screening. In the 50 years since that time, advances in imaging, research, and clinical trials…
-
Optimizing CT Performance Through Use of Tumor Phantoms
Even the most advanced CT scanners available face limitations in their ability to measure small lung nodules. This is a concern since small errors in two-dimensional measures can quickly balloon to become large errors in predicted volume change. As Ricardo S. Avila, of Accumetra, LLC, explained, an axial CT image of a 6.0 by 3.6…
-
IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation Strategies
Although clinical trials are vitally important to researchers working to improve therapies for lung cancer, clinical trials also provide what could be lifesaving treatments to those patients on trials. When there is a disruption to the clinical trial pipeline—anything from funding to barriers to in-person site visits for treatments and follow up exams— lung cancer…
-
Advancing Combined Modality Therapy for Early-Stage, Screen-Detected Disease: Adjuvant/Neoadjuvant Therapy
During the 17th annual Quantitative Imaging Workshop held in late Fall 2020, the Initiative for Early Lung Cancer Research on Treatment (IELCART) offered two sessions with panel discussions exploring the curative potential and challenges of managing early-stage, screen-detected lung cancer. IELCART investigators with well-established screening programs are recognizing a shift in the proportion of early-stage…
-
Differences in Smoking and Lung Cancer Incidence Among Black and White Young Adults in the United States
In the United States, racial disparities in lung cancer incidence are known to exist. This is most likely caused by higher smoking prevalence among non-Hispanic Black adults compared to non-Hispanic White adults.1 In addition, a higher tobacco-associated lung cancer risk for Black adults has been observed.2 Recently, Jemal et al. described their findings of changes…
-
Prolonging CT Screening Intervals is Deemed Safe in Individuals with Negative Baseline Results
In his May 7 presentation “Advance Lung Cancer Screening Globally,” Dr. Pastorino, co-chair of the CT Screening Symposium and director of the Thoracic Surgery Division at the Istituto Nazionale Tumori in Milan, discussed the MILD, BioMILD, and SMILE trials. He also is chair of the IASLC’s Screening and Early Detection Committee.
-
The IASLC Mourns the Loss of Dr. Gouri Bhattacharyya
Gouri Shankar Bhattacharyya, MD, FRCP, died this past week of COVID-19–related complications. A medical oncologist in Kolkata, India, with 25 years of experience, Dr. Bhattacharyya’s special interests were many and included biologic response modifiers, the tumor microenvironment, palliative care, and geriatric oncology. The International Association for Hospice and Palliative Care awarded him with a certificate…